Of 34 patients in parts 1 and 2A, 12 (35.3%) had grade 3 or higher AEs; 4 (11.8%) were considered treatment-related: part 1, aspartate transaminase and alanine transaminase elevations (dostarlimab 10 mg/kg) and increased lipase (dostarlimab 1 mg/kg); and part 2A, fatigue (dostarlimab 500 mg Q3W) and pneumonitis (dostarlimab 1000 mg Q6W) (Table 3). This evidence concerns the gene GPT and pneumonitis.